UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004586
Receipt number R000005479
Scientific Title A phaseII randomized trial of UFT for the patients completely resected pathological Breast cancer
Date of disclosure of the study information 2010/11/19
Last modified on 2010/11/18 19:56:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phaseII randomized trial of UFT for the patients completely resected pathological Breast cancer

Acronym

A phaseII randomized trial of UFT for the patients completely resected pathological Breast cancer
Ryukyu Breast club 002 study

Scientific Title

A phaseII randomized trial of UFT for the patients completely resected pathological Breast cancer

Scientific Title:Acronym

A phaseII randomized trial of UFT for the patients completely resected pathological Breast cancer
Ryukyu Breast club 002 study

Region

Japan


Condition

Condition

Breast cancer

Classification by specialty

Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To study the efficacy of UFT after standard chemotherapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

5-year Disease free survival

Key secondary outcomes

Overall survival, Incidence of adverse events, Feasibility


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Follow up with no treatment until the metastasis or the relapse are confirmed after neo-adjvant chemotherapy or adjvant chemotherapy by standard regimen with evidence

Interventions/Control_2

UFT (250mg/m2/day) is administered orally on days 1-5 of every week for 2 year after neo adjvant chemotherapy or adjvant chemotherapy by standard regimen with evidence

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >

Gender

Female

Key inclusion criteria

1. Intermediate and high risk for recurrence according to the classification proposed by St.Gallen, 2007
2. Histologically confirmed Breast Cancer .
3. Receive neo-adjvant chemotherapy or adjvant chemotherapy by standerd regimen with evidence.
4. Within 12 weeks after standard regimen chemotherapy.
5. The patient has been confirmed to be HER2 negative.
6. Age >=20 to <70 years
7. ECOG Performance status 0-1
8. Oral intake is possible
9. Sufficient organ function.
WBC >=3,500, <12,000/mm3
or Neutrophil >=1,500
Platelet >=100,000/mm3
Hemoglobin >=9.0g/dl
Total bilirubin <1.5 mg/dL
AST and ALT <100 IU/L
Serum creatinine <1.5 mg/dL
10. Written informed consent

Key exclusion criteria

1. HER2 positive
2. Severe complications (uncontrolled diabetes mellitus, infection, heart failure which needs medical treatment (unstable angina pectoris, history of myocardial infarction occurred within 6 months), mental disorder)
3. Interstitial lung disease, pulmonary fibrosis
4. History of serious drug allergy
5. Active other malignancies
6. During pregnancy or lactation.
7. Patients judged inappropriate by physicians

Target sample size

140


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kyuichiro Miyara

Organization

Miyara Clinic

Division name

Breast Oncology

Zip code


Address

2-3-1 Iso, Urasoe, Okinawa, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Koichi Kuninaka

Organization

University of the Ryukyus Hospital

Division name

Surgery1

Zip code


Address

207 Uehara, Nisihara, Nakagamigun, Okinawa, Japan

TEL

098-895-1163

Homepage URL


Email



Sponsor or person

Institute

Ryukyu Breast Club

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 11 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2010 Year 08 Month 20 Day

Date of IRB


Anticipated trial start date

2010 Year 10 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 11 Month 18 Day

Last modified on

2010 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005479


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name